MIRAMAR, Fla., April 9, 2026
DifGen Pharmaceuticals LLC, in collaboration with Apotex Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Nintedanib Soft Gel Capsules, 100 mg and 150 mg, a generic version therapeutically equivalent to Ofev®. This approval represents a major milestone in advancing complex generic drug development and improving patient access to affordable pharmaceutical therapies in the United States, particularly for conditions requiring long-term treatment.
FDA Approval Strengthens Complex Generics Portfolio
The approval of Nintedanib soft gel capsules highlights DifGen’s expertise in developing complex dosage forms, especially soft gelatin formulations that require advanced technical capabilities in formulation, encapsulation, and stability management. As an AB-rated generic, the product has demonstrated bioequivalence and therapeutic equivalence, ensuring that it delivers the same safety, efficacy, and clinical performance as the branded reference drug.
This milestone reflects DifGen’s strong foundation in integrated pharmaceutical development, including formulation science, analytical testing, quality assurance, and regulatory compliance, all of which are critical for successfully navigating the stringent FDA approval process.
Strategic Collaboration Drives U.S. Market Access
Advertisement
Through this collaboration, Apotex Inc. will lead the commercialization and distribution of the approved product across the U.S. healthcare system. This partnership combines DifGen’s manufacturing and development capabilities with Apotex’s established market presence and distribution network, ensuring efficient access to this important therapy. The introduction of this generic drug aligns with broader industry efforts to expand treatment availability, reduce healthcare costs, and improve patient outcomes. By increasing competition in the market for complex therapies, this approval is expected to contribute to greater affordability and accessibility for patients who depend on essential medications.
cGxP Compliance and Quality Systems in Focus
From a cGxP perspective, this approval underscores the importance of maintaining robust quality systems and strict regulatory compliance throughout the drug development lifecycle. The successful approval of a complex generic product requires adherence to current Good Manufacturing Practices (cGMP), validated manufacturing processes, and comprehensive bioequivalence and analytical studies. DifGen’s achievement demonstrates its commitment to USFDA-compliant manufacturing standards, ensuring consistent product quality and reliability.
The development of soft gel capsules, in particular, involves specialized equipment and precise process control, highlighting the company’s ability to meet the highest regulatory and quality benchmarks in pharmaceutical manufacturing.
The FDA approval of Nintedanib Soft Gel Capsules by DifGen Pharmaceuticals and Apotex Inc. marks a significant advancement in the field of complex generics and pharmaceutical innovation, reinforcing the importance of quality, compliance, and strategic collaboration in delivering accessible healthcare solutions. By enabling the availability of cost-effective, therapeutically equivalent treatments, this milestone supports improved patient care while strengthening the generic drug landscape in the United States. As the demand for affordable medicines continues to grow, such developments will play a crucial role in ensuring sustainable healthcare systems and broader patient access to essential therapies.
Source: DifGen Pharmaceuticals press release
